Aclaris Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Aclaris Therapeutics, Inc. (ACRS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-132.07-88.48-86.91-90.87-51.02-161.35-132.74
Depreciation & Amortization0.810.860.800.921.326.411.88
Deferred Income Tax0.00-0.370.000.00-0.180.000.00
Stock Based Compensation10.8620.5415.0414.0611.210.000.00
Change in Working Capital10.929.39-1.20-1.34-2.36-2.709.44
Change in Accounts Receivable-0.020.190.140.154.900.000.00
Change in Accounts Payable-4.19-1.470.373.66-5.220.000.00
Change in Other Working Capital-8.80-20.27-1.7024.34-2.040.000.00
Other Operating Activities2.5027.174.7014.0611.2162.320.56
Net Cash from Operating Activities-20.08-78.33-67.57-52.13-41.03-95.33-100.81
Investing Activities
Capital Expenditures-0.121.31-0.610.310.451.61-1.36
Acquisitions0.00-26.904.7024.342.390.73-67.12
Purchases of Investments-33.84-135.6813.23-235.156.840.000.00
Sales/Maturities of Investments-35.81-135.68177.99-167.326.8473.1177.85
Other Investing Activities-35.810.000.000.002.390.730.00
Net Cash from Investing Activities-69.7746.2212.63-167.638.7872.239.37
Financing Activities
Debt Repayment0.000.000.00-11.48-0.14-0.52-0.65
Common Stock Issued80.0326.7172.90238.20-0.210.00100.21
Common Stock Repurchased-0.41-0.10-0.03-3.120.000.000.00
Other Financing Activities-5.09-0.10-0.03-3.12-0.210.00-1.78
Net Cash from Financing Activities74.5426.7172.87225.0510.64-30.32128.26
Summary
Net Change in Cash-15.31-5.4017.935.29-21.61-53.4236.82
Cash at Beginning of Period39.8845.2827.3522.0635.9457.0220.20
Cash at End of Period24.57-215.3145.2822.0614.333.6057.02
Free Cash Flow-20.20-79.63-68.17-52.44-41.48-96.94-102.17